Human Leucocyte Antigen-G5 As A Biomarker of Tolerance in Kidney Transplant Recipients Could Reflect the Degree of Immune Hyporesponsiveness
Z. -K. Jin,P. -X. Tian,W. -J. Xue,X. -M. Ding,J. Zheng,C. -G. Ding,G. -Q. Ge,T. -C. Mao,W. -L. Duan,M. Xi
DOI: https://doi.org/10.1097/00007890-201211271-02326
2012-01-01
Transplantation
Abstract:Introduction: In the field of solid organ transplantation, two different areas have developed: the use of biomarkers to predict allograft tolerance, and biomarkers for the prediction of allograft rejection. In the present study, we investigate the expression of serum human leucocyte antigen-G5 (HLA-G5) in kidney transplant recipients with different post-transplant time and different immune status, which to predict immune hyporesponsiveness in transplant recipients. Methods: The study was approved by the local ethical committee. All patients with end-stage renal disease underwent kidney transplantation with living-related donor. Eleven kidney transplant recipients with normal renal graft were selected in which the dynamic expression of serum HLA-G5 was detected by ELISA method during pre-transplantation and the first year post-transplantation. Thirty three kidney transplant recipients with normal renal graft were selected divided into three groups that 1˜5 years, 5˜10 years and 10 years later post transplantation. Investigate the expression of serum HLA-G5 in recipients during one year later post transplantation. Twenty recipients with acute rejection were selected as acute rejection group, and ten healthy volunteers were selected as healthy control. Results: The levels of serum HLA-G5 had no significant difference between groups of pre-transplantation and normal control (83.27±21.85 U/mL vs. 77.31±23.00 U/mL, P>0.05), and the same results between groups of a week and a month post-transplantation (90.57±16.61 U/mL vs. 93.28±17.32 U/mL, P>0.05). The levels of serum HLA-G5 in group of 3 months post-transplantation significant higher than group of one month post-transplantation (125.79±17.87 U/mL vs. 93.28±17.32 U/mL, P< 0.001). There were no significant difference among 3 months, 6 months and 12 months post transplantation (125.79±17.87 U/mL vs. 127.15±19.10 U/mL vs. 130.96±29.84 U/mL, P>0.05), and between groups of 1˜5 years and 5˜10years post-transplantation (211.75±28.34 U/mL vs. 273.08±131.49 U/mL, P>0.05), and between groups of 10 years later (294.90±123.00 U/mL) and 5˜10years post transplantation (P>0.05). The levels of serum HLA-G5 in group of 10 years later post-transplantation significant higher than group of 1˜5 years post-transplantation (P< 0.05). The levels of HLA-G5 were significant correlated with the post-transplant time in the first year post-transplantation and in one year later post transplantation (r=0.599, r=0.522, P< 0.01). The levels of serum HLA-G5 in all groups of recipients significant higher than group of acute rejection (67.57±23.55U/mL). Conclusions: This study showed increased serum concentration of HLA-G5 in the patients with long term graft and recipents survival compared with acute rejection, and the levels of HLA-G5 were significant correlated with the post-transplant time, which reflect the degree of immune hyporesponsiveness in anti-renal allograft by recipients. Therefore, monitoring of HLA-G5 in the peripheral blood as a biomarker of tolerance may reflect unresponsiveness to the graft and reflect the immune state of kidney transplant recipients, and may be an important reference to guide post-transplant immunosuppressive therapy.